13 completed, 7 unknown, 4 recruiting, 4 terminated. 35 Phase 2, 6 Phase 1, 4 Phase 3.
Follow Cancer Pain: new trials by email Literature Review of Cancer Pain trials Research Report on Cancer Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain 3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa) - Cancer Pain | Phase 2 | Not yet recruiting | 3D Medicines | 177 | 2026-12-01 | 2026-03-11 |
| Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain Resiniferatoxin - Intractable Pain, Palliative Care | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2026-11-27 | 2026-10-29 |
| Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain On the basis of conventional analgesia, patients receive treatment with Gutong Plaster. - Cancer Pains | Phase 1 / Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 198 | 2025-12-25 | 2026-06-18 |
| Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) VMD-3866 Gel, Placebo Gel - Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain | Phase 2 | Recruiting | VM Therapeutics LLC | 16 | 2025-12-12 | 2026-10-21 |
| Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer Resiniferatoxin, Placebo - Pain, Intractable, Pain Cancer | Phase 2 | Suspended | Sorrento Therapeutics, Inc. | 120 | 2025-09-01 | 2024-03-18 |
| Unique Treatment of Oncology Pain in Advanced Cancer Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene) - Cancer Pain | Phase 2 | Completed | ZYUS Life Sciences Inc. | 11 | 2025-06-12 | 2026-09-01 |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain Halneuron, Placebo, Halneuron (Open Label Extension) - Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy | Phase 2 | Active not recruiting | Dogwood Therapeutics Inc. | 240 | 2025-02-21 | 2026-09-16 |
| Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors Mindfulness Oriented Recovery Enhancement (MORE), Questionnaires, Supportive Psychotherapy (SG) - Breast Cancer Survivor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 200 | 2024-12-06 | 2026-09-22 |
| Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain Injection of humanized nerve growth factor (NGF) antibody - Cancer Pain | Phase 1 / Phase 2 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 132 | 2024-03-27 | 2025-06-06 |
| Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds Morphine Sulfate, Lidocaine Hcl 2% Jelly - Wounds and Injuries, Cancer Pain | Phase 2 | Unknown | Instituto Nacional de Cancer, Brazil | 106 | 2023-09-12 | 2023-09-28 |
| Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator - Nausea Post Chemotherapy, Vomiting | Phase 1 / Phase 2 | Unknown | LaSanta S A S | 334 | 2023-08-15 | 2023-02-01 |
| Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief MORE treatments, Standard of Care for Pain Management - Chronic Pain, Cancer Pain | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 76 | 2023-05-16 | 2026-09-25 |
| Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial ELEQUIL - Cancer Pain | Phase 2 | Completed | M.D. Anderson Cancer Center | 70 | 2022-05-18 | 2024-12-02 |
| Fluoroscopic Anterior Approach Versus Ultrasound Guided Superior Hypogastric Plexus Neurolysis in Cancer Pelvic Pain Group US-guided, Group fluoroscopy-guided - Pain Cancer | Phase 2 | Unknown | Mansoura University | 96 | 2022-01-01 | 2022-08-16 |
| The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy Venlafaxine, Memantine - Oncology Pain, Chemotherapy-induced Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Mendel AI | 60 | 2021-02-15 | 2021-02-04 |
| Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain esketamine nasal spray, placebo nasal spray - Cancer Pain | Phase 2 | Withdrawn | University Hospital, Basel, Switzerland | 2020-11-25 | 2023-10-19 | |
| Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer PPP001, Placebo - Cancer Pain, Quality of Life | Phase 2 | Unknown | Tetra Bio-Pharma | 78 | 2020-07-30 | 2021-09-16 |
| Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration PCA IV Hydromorphone (continuous dose = 0), PCA IV Hydromorphone (continuous dose ≠ 0), Oral morphine - Cancer Pain | Phase 2 | Completed | Fujian Cancer Hospital | 95 | 2020-04-10 | 2021-03-05 |
| Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol Oral tablet - Steroid Anlgesia in Cancer Pain | Phase 2 | Completed | Mansoura University | 39 | 2019-11-15 | 2020-03-10 |
| Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT) Acupuncture, Massage - Cancer Pain | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 300 | 2019-09-17 | 2026-10-14 |
Showing 20 of 35. Sign in to see all of them.
Pain (14) · Neoplasms (12) · Agnosia (3) · Breast Neoplasms (3) · Pain, Intractable (3) · Chronic Pain (2) · Neuralgia (2) · Acute Pain (1) · Arthralgia (1) · Bone Neoplasms (1) · Colorectal Neoplasms (1) · Constipation (1) · Disease (1) · Head and Neck Neoplasms (1)
Neurologic Manifestations (35) · Pathological Conditions, Signs and Symptoms (35) · Signs and Symptoms (35) · Pain (21) · Nervous System Diseases (4) · Breast Diseases (3) · Neoplasms by Site (3) · Neurobehavioral Manifestations (3) · Perceptual Disorders (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Musculoskeletal Diseases (2) · Neuromuscular Diseases (2)
Dronabinol (2) · Ketamine (2) · Lidocaine (2) · Morphine (2) · resiniferatoxin (2) · Acetaminophen (1) · Acupuncture Therapy (1) · Animal Assisted Therapy (1) · Antibodies (1) · Cannabidiol (1) · Fentanyl (1) · Gels (1) · Glucose (1) · Lenalidomide (1) · Massage (1)
Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (2) · Mansoura University (2) · 3D Medicines (1) · Barretos Cancer Hospital (1) · British Columbia Cancer Agency (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Center for Medicinal Cannabis Research (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Dogwood Therapeutics Inc. (1) · Emory University (1) · Faculdade de Medicina do ABC (1) · Fujian Cancer Hospital (1) · InSightec (1) · Instituto Nacional de Cancer, Brazil (1)
United States (16) · China (4) · Canada (3) · Egypt (3) · Poland (3) · South Korea (3) · Brazil (2) · France (2) · Hungary (2) · India (2) · Portugal (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Jun Mao, MD, MSCE (2) · Ann M Cohen Berger, M.D. (1) · Auro del Giglio (1) · Bahman Jabbari, MD (1) · Benito Benitez, MD (1) · Daniel IG Cubero (1) · Donald I Abrams, M.D. (1) · John D Heiss, M.D. (1) · Julie Stakiw, MD (1) · Jun J Mao, MD, MSCE (1)
PMID 10506634, PMID 11027905, PMID 11387363, PMID 11576800, PMID 1349061, PMID 14701781, PMID 15310785, PMID 16051965, PMID 17355955, PMID 22965960, PMID 25919474, PMID 28657160, PMID 33732434, PMID 36575390, PMID 36581960, PMID 37962891, PMID 38502819, PMID 38752431, PMID 38977653, PMID 41490669, PMID 8577492, PMID 9779694, PMID 9817288
2008 (2)